Corvus Pharmaceuticals, Inc.(CRVS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CRVS Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Corvus Pharmaceuticals, Inc. (CRVS), a Healthcare sector company. CRVS is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Corvus Pharmaceuticals, Inc. reports net income of $-18.0M, free cash flow of $-16.0M. Top institutional holders of CRVS by reported 13-F value include ORBIMED ADVISORS, BlackRock, STATE STREET, based on the most recent SEC filings. CRVS trades on the Nasdaq exchange and files with the SEC under CIK 1626971. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRVS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Corvus Pharmaceuticals, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-18.0M
Free Cash Flow
Q2 2026
$-16.0M
ROIC
Q2 2026
-34.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+75.5% YoYOperating Income
-56.0% YoYEPS (Diluted)
+48.0% YoYTotal Assets
+3.2% YoYOp. Cash Flow
-29.0% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-15.3M +75.5% | $-62.3M -130.5% | $-27.0M +34.6% | $-41.3M +4.5% | $-43.2M -621.3% | $-6.0M |
| Operating Income | $-43.0M -56.0% | $-27.5M -17.7% | $-23.4M +28.1% | $-32.6M +15.7% | $-38.6M +11.7% | $-43.8M |
| EPS (Diluted) | $-0.53 +48.0% | $-1.02 -82.1% | $-0.56 +37.1% | $-0.89 +13.6% | $-1.03 -415.0% | $-0.20 |
| Total Assets | $71.1M +3.2% | $68.9M +51.3% | $45.6M -33.2% | $68.2M -37.7% | $109.5M +28.0% | $85.5M |
| Operating Cash Flow | $-32.8M -29.0% | $-25.4M -6.2% | $-23.9M +11.4% | $-27.0M +26.4% | $-36.7M -5.6% | $-34.8M |
| Free Cash Flow | $-33.0M | — | $-24.0M +12.2% | $-27.3M +25.7% | $-36.7M -5.4% | $-34.9M |
Get alerted when CRVS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Corvus Pharmaceuticals, Inc. including:
Top Institutional Holders of CRVS
ORBIMED ADVISORS LLC
$107.0M7,165,006 shBlackRock, Inc.
$106.7M7,138,811 shSTATE STREET CORP
$66.8M4,474,091 shPRICE T ROWE ASSOCIATES INC /MD/
$56.6M3,789,126 shVANGUARD CAPITAL MANAGEMENT LLC
$49.2M3,292,710 shADAMS STREET PARTNERS LLC
$48.9M3,275,616 shVivo Capital, LLC
$41.9M2,805,816 shWELLINGTON MANAGEMENT GROUP LLP
$40.8M2,731,632 shPERCEPTIVE ADVISORS LLC
$39.9M2,667,441 shDeep Track Capital, LP
$37.2M2,491,939 sh
| Fund | Value | Shares |
|---|---|---|
| ORBIMED ADVISORS LLC | $107.0M | 7,165,006 |
| BlackRock, Inc. | $106.7M | 7,138,811 |
| STATE STREET CORP | $66.8M | 4,474,091 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $56.6M | 3,789,126 |
| VANGUARD CAPITAL MANAGEMENT LLC | $49.2M | 3,292,710 |
| ADAMS STREET PARTNERS LLC | $48.9M | 3,275,616 |
| Vivo Capital, LLC | $41.9M | 2,805,816 |
| WELLINGTON MANAGEMENT GROUP LLP | $40.8M | 2,731,632 |
| PERCEPTIVE ADVISORS LLC | $39.9M | 2,667,441 |
| Deep Track Capital, LP | $37.2M | 2,491,939 |
More Healthcare Companies
View all Healthcare →Put CRVS on your watchlist
Track score changes the day Corvus Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CRVS a good stock to buy?
13F Pro's AI-powered analysis of Corvus Pharmaceuticals, Inc. (CRVS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRVS are available on the CRVS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CRVS is classified as a small company.
Which hedge funds own CRVS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRVS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Corvus Pharmaceuticals, Inc.'s investment landscape.